Literature DB >> 12871586

Opposite regulation by typical and atypical anti-psychotics of ERK1/2, CREB and Elk-1 phosphorylation in mouse dorsal striatum.

Laura Pozzi1, Kerstin Håkansson, Alessandro Usiello, Anders Borgkvist, Maria Lindskog, Paul Greengard, Gilberto Fisone.   

Abstract

The two mitogen-activated protein kinases (MAPKs), extracellular signal-regulated protein kinase 1 and 2 (ERK1/2), are involved in the control of gene expression via phosphorylation and activation of the transcription factors cyclic AMP response element binding protein (CREB) and Elk-1. Here, we have examined the effect of haloperidol and clozapine, two anti-psychotic drugs, and eticlopride, a selective dopamine D2 receptor antagonist, on the state of phosphorylation of ERK1/2, CREB and Elk-1, in the mouse dorsal striatum. Administration of the typical anti-psychotic haloperidol stimulated the phosphorylation of ERK1/2, CREB and Elk-1. Virtually identical results were obtained using eticlopride. In contrast, the atypical anti-psychotic clozapine reduced ERK1/2, CREB and Elk-1 phosphorylation. This opposite regulation was specifically exerted by haloperidol and clozapine on ERK, CREB, and Elk-1 phosphorylation, as both anti-psychotic drugs increased the phosphorylation of the dopamine- and cyclic AMP-regulated phosphoprotein of 32 kDa (DARPP-32) at the cyclic AMP-dependent protein kinase (PKA) site. The activation of CREB and Elk-1 induced by haloperidol appeared to be achieved via different signalling pathways, as inhibition of ERK1/2 activation abolished the stimulation of Elk-1 phosphorylation without affecting CREB phosphorylation. This study shows that haloperidol and clozapine induce distinct patterns of phosphorylation in the dorsal striatum. The results provide a novel biochemical paradigm elucidating the molecular mechanisms underlying the distinct therapeutic actions of typical and atypical anti-psychotic agents.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871586     DOI: 10.1046/j.1471-4159.2003.01851.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  40 in total

1.  DARPP-32: A molecular switch at the nexus of reward pathway plasticity.

Authors:  Todd D Gould; Husseini K Manji
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-04       Impact factor: 11.205

2.  Evaluation of neuronal phosphoproteins as effectors of caffeine and mediators of striatal adenosine A2A receptor signaling.

Authors:  Bogachan Sahin; Stacey Galdi; Joseph Hendrick; Robert W Greene; Gretchen L Snyder; James A Bibb
Journal:  Brain Res       Date:  2006-12-06       Impact factor: 3.252

3.  Changes in prefrontal and amygdala activity during olanzapine treatment in schizophrenia.

Authors:  Giuseppe Blasi; Teresa Popolizio; Paolo Taurisano; Grazia Caforio; Raffaella Romano; Annabella Di Giorgio; Fabio Sambataro; Valeria Rubino; Valeria Latorre; Luciana Lo Bianco; Leonardo Fazio; Marcello Nardini; Daniel R Weinberger; Alessandro Bertolino
Journal:  Psychiatry Res       Date:  2009-05-09       Impact factor: 3.222

Review 4.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

5.  Haloperidol regulates the state of phosphorylation of ribosomal protein S6 via activation of PKA and phosphorylation of DARPP-32.

Authors:  Emmanuel Valjent; Jesus Bertran-Gonzalez; Heather Bowling; Sébastien Lopez; Emanuela Santini; Miriam Matamales; Alessandra Bonito-Oliva; Denis Hervé; Charles Hoeffer; Eric Klann; Jean-Antoine Girault; Gilberto Fisone
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

6.  Discovery and characterization of a G protein-biased agonist that inhibits β-arrestin recruitment to the D2 dopamine receptor.

Authors:  R Benjamin Free; Lani S Chun; Amy E Moritz; Brittney N Miller; Trevor B Doyle; Jennie L Conroy; Adrian Padron; Julie A Meade; Jingbo Xiao; Xin Hu; Andrés E Dulcey; Yang Han; Lihua Duan; Steve Titus; Melanie Bryant-Genevier; Elena Barnaeva; Marc Ferrer; Jonathan A Javitch; Thijs Beuming; Lei Shi; Noel T Southall; Juan J Marugan; David R Sibley
Journal:  Mol Pharmacol       Date:  2014-04-22       Impact factor: 4.436

7.  D1 and D2 dopamine receptors differentially mediate the activation of phosphoproteins in the striatum of amphetamine-sensitized rats.

Authors:  Xiangdang Shi; Jacqueline F McGinty
Journal:  Psychopharmacology (Berl)       Date:  2010-11-06       Impact factor: 4.530

8.  Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: implications for neurodegeneration.

Authors:  Jonathan Kipnis; Michal Cardon; Hila Avidan; Gil M Lewitus; Sharon Mordechay; Asya Rolls; Yael Shani; Michal Schwartz
Journal:  J Neurosci       Date:  2004-07-07       Impact factor: 6.167

Review 9.  The neurotrophic and neuroprotective effects of psychotropic agents.

Authors:  Joshua Hunsberger; Daniel R Austin; Ioline D Henter; Guang Chen
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

10.  Clozapine-induced ERK1 and ERK2 signaling in prefrontal cortex is mediated by the EGF receptor.

Authors:  Avril Pereira; George Fink; Suresh Sundram
Journal:  J Mol Neurosci       Date:  2009-03-10       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.